Promethazin-Codein-Lösung zum Einnehmen

Produkt Beschreibung

1. Classification and Chemical Overview

Promethazine with Codeine Oral Solution (frequently referred to historically under discontinued innovator trade names such as Phenergan with Codeine, or colloquially in illicit drug subcultures as “syrup,” “purple drank,” or “lean”) is a dual-constituent liquid pharmaceutical preparation. It combines an opioid antitussive/analgesic with a sedating first-generation phenothiazine antihistamine:

• Codeine Phosphate: Chemically designated as $(5R,6S,9R,13S,14R)\text{-3-methoxy-17-methyl-4,5-epoxymorphin-6-ol phosphate hemihydrate}$. It is a naturally occurring or semi-synthetic phenanthrene alkaloid that functions as a centrally acting, weak-to-moderate $\mu\text{-opioid}$ receptor agonist via metabolic bioactivation. Its molecular formula is $\text{C}_{18}\text{H}_{21}\text{NO}_3\cdot\text{H}_3\text{PO}_4\cdot\frac{1}{2}\text{H}_2\text{O}$ with a molecular weight of approximately $406.4\text{ g/mol}$.

• Promethazine Hydrochloride: Chemically designated as $(RS)\text{-N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine monohydrochloride}$. It is a neuroleptic-derived ethylamino derivative of phenothiazine functioning as a potent, competitive histamine $H_1$ receptor antagonist with marked central anticholinergic (muscarinic), antiemetic, and $\alpha_1$-adrenergic blocking properties. Its empirical formula is $\text{C}_{17}\text{H}_{20}\text{N}_2\text{S}\cdot\text{HCl}$ with a molecular weight of $320.88\text{ g/mol}$.

Standard pharmaceutical formulations (originating predominantly in North American and specialized international pharmacopeias) deliver $10\text{ mg}$ of codeine phosphate und $6.25\text{ mg}$ of promethazine hydrochloride per $5\text{ mL}$ of oral solution (often compounded with $7\%\text{ v/v}$ ethanol, sodium benzoate, sodium citrate, saccharin/sucrose, citric acid, and artificial red/purple dyes).

Within regulatory frameworks:

• UK Classification: Fixed-dose liquid combinations of promethazine and codeine are not marketed as standard licensed proprietary medicines in the United Kingdom (unlike individual formulations of codeine linctus or promethazine oral elixir). Under the Human Medicines Regulations 2012, equivalent preparations are categorized as Prescription Only Medicines (POM). Under the Misuse of Drugs Act 1971 and Misuse of Drugs Regulations 2001, the codeine component places the solution under Class B, Schedule 5 (when below specific concentration cut-offs and formulated with other non-controlled active ingredients) or Class B, Schedule 2 depending on formulation concentration and scheduling thresholds.

• US / International Classification: Controlled under the US Controlled Substances Act as a Schedule V prescription narcotic, subjected to strict manufacturing quotas, distributor tracking, and widespread regional discontinuations by pharmaceutical innovators due to rampant diversion.

In contemporary forensic toxicology and harm reduction, Promethazine with Codeine Oral Solution is recognized as the definitive active formulation for recreational “lean” consumption. Commercial bottles circulating on grey markets or darknet platforms represent a high-risk vector for counterfeit pharmaceuticals, which frequently substitute active APIs with lethal synthetic nitazene analogues (e.g., isotonitazene, metonitazene) or fentanyl, mixed with over-the-counter antihistamines and industrial colorants.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of the formulation is defined by the complementary and mutually potentiating actions of its two active constituents across the central and peripheral nervous systems:

• Codeine Pharmacodynamics ($\mu$-Opioid Agonism via Morphine):

  • Prodrug Activation: Codeine exhibits minimal intrinsic affinity for human opioid receptors ($\sim 200$-fold lower than morphine). Its primary clinical efficacy requires metabolic bioactivation via the hepatic cytochrome P450 2D6 (CYP2D6) pathway, converting approximately $5\text{ to }10\%$ of the parent drug into free Morphium.

  • Receptor Coupling: Converted morphine binds as a full agonist to human $\mu\text{-opioid}$ (MOP) receptors (coupled to inhibitory $G_{\alpha i/o}$ proteins). This suppresses adenylyl cyclase, lowers intracellular cyclic adenosine monophosphate (cAMP), closes presynaptic voltage-gated N-type calcium channels, and opens postsynaptic G-protein-coupled inwardly rectifying potassium (GIRK) channels. This blocks nociceptive transmission across the dorsal horn of the spinal cord and periaqueductal gray.

  • Medullary Antitussive Reflex Suppression: Codeine directly suppresses the central cough reflex at the cough center located within the nucleus tractus solitarii of the medulla oblongata, partly through non-opioid $\sigma\text{-receptors}$ and distinct cough-regulatory receptors.

• Promethazine Pharmacodynamics (Multireceptor Antagonism):

  • Histamine $H_1$ Antagonism: Promethazine acts as a high-affinity, competitive antagonist at central and peripheral $H_1$ receptors. Central $H_1$ blockade within the tuberomammillary nucleus of the hypothalamus disrupts arousal and vigilance networks, mediating profound sedation and somnolence.

  • Muscarinic Anticholinergic Blockade: It acts as a potent antagonist at central and peripheral muscarinic acetylcholine receptors ($M_1\text{ to }M_5$), suppressing vestibular and autonomic inputs, drying mucosal secretions, and inducing parasympatholytic effects (pupillary dilation, tachycardia, urinary hesitancy, constipation).

  • Antiemetic Actions: Direct blockade of dopamine $D_2$ und $H_1$ receptors in the chemoreceptor trigger zone (CTZ) of the area postrema suppresses the emetic reflex, counteracting opioid-induced nausea.

• Pharmacodynamic Synergism (The “Lean” Triad):

  • Sedative Amplification: Dual central depression (opioid-induced reduction in locus coeruleus firing combined with antihistaminergic/anticholinergic hypothalamic suppression) produces synergistic, profound sedation and dissociation.

  • Blunted Defensive Reflexes: Promethazine inhibits codeine-mediated nausea and vomiting (facilitating the ingestion of massive, supratherapeutic opioid doses), while attenuating codeine-induced peripheral histamine release (preventing pruritus and facial flushing).

  • Compound Medullary Respiratory Depression: Both agents depress the sensitivity of central pontine and medullary respiratory pacemaker neurons to hypercapnic ($\text{CO}_2$) and hypoxic arterial drive, exponentially escalating the risk of fatal central apnea.

3. Approved Clinical Indications and Therapeutic Scope

Where authorized by international drug regulatory agencies, Promethazine with Codeine Oral Solution holds narrow clinical indications:

• Symptomatic Relief of Severe Cough and Upper Respiratory Symptoms: Temporary relief of intractable, non-productive cough, rhinorrhea, and nasal congestion associated with acute viral upper respiratory tract infections or allergies in adults when non-opioid alternatives (e.g., guaifenesin, dextromethorphan, simple linctus) have failed.

  • Standard Adult Dosing: $5\text{ mL}$ ($10\text{ mg}$ codeine / $6.25\text{ mg}$ promethazine) orally every 4 to 6 hours as clinically indicated (maximum licensed ceiling: $30\text{ mL}$ within 24 hours).

• Strict Contraindication in Paediatrics (<18 Years): Following comprehensive safety reviews by the UK MHRA, European Medicines Agency (EMA), and US Food and Drug Administration (FDA), opioid-containing cough and cold medications (including codeine/promethazine combinations) are strictly contraindicated in children and adolescents under 18 years of age due to fatal respiratory depression risks, especially following tonsillectomy, adenoidectomy, or in the presence of underlying respiratory disease.

In the UK, NICE Clinical Knowledge Summaries (CKS: Cough) explicitly discourage the use of opioid antitussives for acute cough management, citing negligible evidence of clinical efficacy, high risk of tolerance, and abuse liability.

The practical presentation of this solution is heavily dominated by non-medical, recreational abuse:

• Recreational “Lean” / “Sizzurp” Misuse: Formulated by mixing excessive volumes ($60\text{ to }240\text{ mL}$, containing $120\text{ to }480\text{ mg}$ of codeine and $75\text{ to }300\text{ mg}$ of promethazine) with carbonated soft drinks and fruit-flavored candies, consumed continuously over several hours.

• Polydrug Stacking: Frequently consumed alongside cannabis, benzodiazepines, or alcohol to intensify euphoric dissociation and sedation.

This fixed combination is absent from the routine NHS Drug Tariff, cannot be prescribed on standard primary care FP10 forms, and is treated as an illicitly diverted or imported substance when encountered clinically in the UK.

4. Pharmacokinetic Profile and Metabolic Fate

The clinical presentation and toxicity of this formulation depend on parallel, interacting metabolic pathways and critical pharmacogenetic variations:

Pharmacogenetic and Metabolic Pitfalls

• The CYP2D6 Metabolic Trap:

  • Poor Metabolisers (PMs; $7\text{ to }10\%$ of Caucasian populations): Inability to bioactivate codeine into morphine, resulting in absent analgesia/euphoria but full susceptibility to promethazine toxicity and codeine adverse events.

  • Ultra-Rapid Metabolisers (UMs; up to $10\%$ of Caucasians, up to $29\%$ of specific African/Middle Eastern cohorts): Gene duplications cause accelerated, massive clearance of codeine into circulating free morphine, precipitating unpredictable, fatal respiratory arrest and coma at therapeutic or sub-therapeutic doses.

• Pharmacokinetic Drug-Drug Interaction: Because promethazine is both a substrate and moderate inhibitor of CYP2D6, its co-administration can theoretically compete with codeine for CYP2D6 clearance, altering the rate of morphine generation and extending codeine systemic half-life.

• Kinetic Mismatch: Promethazine’s prolonged terminal half-life ($10\text{ to }19\text{ hours}$) significantly outlasts codeine ($2.5\text{ to }3.5\text{ hours}$). Repeated recreational re-dosing causes massive systemic accumulation of promethazine, shifting the clinical presentation from opioid euphoria to severe, protracted anticholinergic delirium and extrapyramidal toxicity.

5. Physiological Effects and Adverse Event Spectrum

Therapeutic administration suppresses mucosal secretions, diminishes the cough reflex, and induces mild sedation. In supratherapeutic, recreational, or chronic exposure, it triggers severe multi-system adverse effects:

• Central Nervous System and Neuropsychiatric Toxicity (Very Common, $\ge 1/10$):

  • Severe somnolence, excessive daytime sedation, psychomotor slowing, and cognitive clouding.

  • Anticholinergic Delirium: Provoked by supratherapeutic promethazine doses; characterized by visual and auditory hallucinations, restlessness, disorientation, picking at air/clothes, and memory fragmentation.

  • Seizure Threshold Reduction: Promethazine (as a phenothiazine derivative) lowers central seizure thresholds, predisposing individuals to epileptiform activity and grand mal seizures during acute overdose.

  • Extrapyramidal Symptoms (EPS): Acute dystonic reactions (spasmodic torticollis, oculogyric crises, facial grimacing), akathisia, and tardive-like movements secondary to central $D_2$ receptor blockade.

• Gastrointestinal and Autonomic Disruptions (Common, $1/100$ to $<1/10$):

  • Severe constipation and delayed gastric emptying (compound $\mu\text{-opioid}$ and anticholinergic motility arrest), predisposing to paralytic ileus and toxic megacolon.

  • Xerostomia (dry mouth), blurred vision (cycloplegia and mydriasis), and urinary retention (detrusor muscle relaxation and sphincter constriction).

• Cardiovascular Dysregulation:

  • Postural hypotension, orthostasis, and reflex tachycardia (mediated by peripheral $\alpha_1$-adrenergic antagonism).

  • Cardiac Arrhythmias: Concentration-dependent cardiac QTc interval prolongation, predisposing to polymorphic ventricular tachycardia (Torsades de Pointes) and ventricular fibrillation during acute overdose.

• Severe, Emergent and Life-Threatening Hazards (Overdose & Dependence):

  • Fatal Synergistic Respiratory Arrest: The leading driver of mortality. Suppression of the medullary pre-Bötzinger complex triggers severe bradypnea ($<6\text{ breaths/min}$), profound arterial hypoxemia, respiratory acidosis, coma, and fatal asphyxiation.

  • Neuroleptic Malignant Syndrome (NMS): Rare, life-threatening complication of promethazine exposure; characterized by hyperpyrexia ($>40.0^\circ\text{C}$), “lead-pipe” muscular rigidity, autonomic instability (fluctuating blood pressure, profuse diaphoresis), elevated creatine kinase (CK), and acute rhabdomyolysis.

  • Rapid Physical Dependence and Complex Polysubstance Withdrawal: Regular exposure induces rapid neuroadaptation across $\mu\text{-opioid}$ and muscarinic pathways. Abrupt cessation triggers a compound withdrawal syndrome:

    • Opioid Withdrawal: Severe agitation, rhinorrhea, lacrimation, piloerection (“cold turkey”), gastrointestinal cramping, vomiting, diarrhea, and intense myalgias.

    • Cholinergic Rebound: Sweating, profound insomnia, nausea, tremors, anxiety, and hypersalivation.

  • Adulteration Risks of Illicit “Lean”: Black-market syrup bottles marketed under counterfeit US labels routinely contain synthetic nitazene opioids (which exhibit potencies tens to hundreds of times higher than morphine), precipitating sudden, refractory respiratory arrest that requires massive, escalated doses of naloxone.

6. Contraindications, Drug Interactions, and Clinical Precautions

The evaluation, stabilization, and medical management of individuals exposed to Promethazine with Codeine Oral Solution require adherence to critical toxicological and harm-minimisation standards:

• Contraindications:

  • Children and Adolescents Under 18 Years: Absolute contraindication due to high risk of fatal respiratory depression.

  • Known CYP2D6 Ultra-Rapid Metabolisers: Absolute contraindication (uncontrolled rapid conversion to lethal morphine concentrations).

  • Respiratory Insufficiency: Absolute contraindication in severe asthma, chronic obstructive pulmonary disease (COPD), respiratory depression, or sleep apnea syndromes.

  • Comatose States or CNS Depression: Contraindicated in pre-existing profound sedation or depressed consciousness.

  • Concurrent Monoamine Oxidase Inhibitors (MAOIs): Absolute contraindication during or within 14 days of MAOI therapy (risks hyperpyrexic crises and autonomic collapse).

  • Cardiac Conduction Abnormalities: Contraindicated in baseline QTc prolongation, congenital long QT syndrome, or severe bradycardia.

  • Pregnancy and Breastfeeding: Absolute contraindication during breastfeeding (morphine distributes into breast milk, causing fatal neonatal respiratory depression in nursing infants); chronic use during pregnancy precipitates neonatal opioid withdrawal syndrome (NOWS).

• Drug Interactions:

  • Central Nervous System Depressants (e.g., Alcohol, Benzodiazepines, Barbiturates, GHB/GBL): Synergistic, catastrophic depression of medullary respiratory centers; co-ingestion is the leading cause of accidental “lean” fatalities.

  • CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine, Bupropion, Quinidine): Blocks the metabolic conversion of codeine to morphine, blunting opioid effects while promethazine accumulation and anticholinergic toxicities remain unopposed.

  • Anticholinergic Agents (e.g., Tricyclic Antidepressants, Atropine, Antipsychotics): Additive anticholinergic burden, multiplying risks of severe central delirium, urinary retention, bowel ileus, and hyperthermia.

  • Drugs Prolonging the QTc Interval (e.g., Methadone, Antipsychotics, Macrolides, Antiarrhythmics): Additive cardiotoxicity, substantially increasing the risk of Torsades de Pointes.

• Clinical Precautions and Emergency Management (“Red Flags”):

  • Acute Overdose Resuscitation Protocol: Individuals presenting to NHS emergency departments (999/A&E) with severe somnolence, pinpoint or intermediate pupils, bradypnea ($<8\text{ breaths/min}$), or delirium require immediate emergency care:

    • Airway and Oxygenation: Secure airway patency immediately, position in the lateral recovery position, deliver high-flow oxygen, and provide bag-valve-mask or mechanical ventilation.

    • Targeted Naloxone Administration: Administer the opioid antagonist naloxone ($400\text{ mcg}$ IV initially, repeating or escalating to $800\text{ mcg}$ to $2\text{ mg}$ every 2 to 3 minutes up to $10\text{ mg}$ as needed to restore adequate spontaneous ventilation).

    • Clinical Warning on Incomplete Reversal: While naloxone reverses the $\mu\text{-opioid}$ respiratory depression induced by converted morphine, it does not reverse the profound sedation, anticholinergic delirium, QTc prolongation, or extrapyramidal effects caused by promethazine. Clinicians must anticipate residual sedation and avoid escalating naloxone doses unnecessarily once a respiratory rate $>10\text{ to }12\text{ breaths/min}$ is restored.

    • Extended Monitoring Window: Because converted morphine and promethazine possess elimination half-lives that significantly outlast intravenous naloxone ($30\text{ to }60\text{ minutes}$ duration of action), patients must be observed under continuous pulse oximetry and cardiac telemetry for a minimum of 6 to 12 hours to prevent fatal “re-narcotization.”

  • Managing Extrapyramidal Reactions: Acute dystonic reactions (e.g., oculogyric crisis, torticollis) induced by promethazine’s $D_2$ antagonism should be treated with an anticholinergic antiparkinsonian agent, such as procyclidine ($5\text{ to }10\text{ mg}$ IV/IM).

  • Detoxification Protocols: Dependent individuals attempting to discontinue codeine-promethazine formulations must not be stopped abruptly without medical supervision. Management involves structured stabilization and gradual dose reduction using licensed oral opioid substitution therapy (e.g., buprenorphine or methadone) under NHS community addiction services, coupled with symptomatic management for cholinergic rebound and autonomic distress.

  • Counterfeit Sourcing Warnings: Healthcare professionals engaging with individuals reporting recreational syrup consumption must clearly highlight the life-threatening prevalence of counterfeit bottles laced with synthetic nitazene opioids, explaining that standard opioid dosing expectations are completely invalid when consuming black-market formulations.